MX2016014779A - Prueba de diagnostico y tratamiento/prevencion de la enfermedad de alzheimer. - Google Patents
Prueba de diagnostico y tratamiento/prevencion de la enfermedad de alzheimer.Info
- Publication number
- MX2016014779A MX2016014779A MX2016014779A MX2016014779A MX2016014779A MX 2016014779 A MX2016014779 A MX 2016014779A MX 2016014779 A MX2016014779 A MX 2016014779A MX 2016014779 A MX2016014779 A MX 2016014779A MX 2016014779 A MX2016014779 A MX 2016014779A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- disease
- peptide
- treatment
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
La presente invención incluye un método de diagnóstico y tratamiento y prevención de la Enfermedad de Alzheimer que comprende obtener una muestra biológica de un sujeto sospechoso de tener la Enfermedad de Alzheimer; determinar el nivel de expresión de HSP27, en donde un aumento estadístico significativo expresión de proteína de HSP27 en la muestra en comparación con una muestra de un paciente no enfermo de Alzheimer es indicativo de que el sujeto tiene la Enfermedad de Alzheimer? y modificar el tratamiento del sujeto como resultado de la detección de la Enfermedad de Alzheimer al proporcionar al sujeto una terapia estándar o un vector simple que expresa un péptido trimétrico AB42 y opcionalmente la adicción de un péptido AB42, que provoca una reacción inmune contra el péptido AB42, proveniente de esta manera la acumulación del péptido AB42 y por lo tanto previniendo o tratando la Enfermedad de Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461994644P | 2014-05-16 | 2014-05-16 | |
PCT/US2015/031011 WO2015175898A1 (en) | 2014-05-16 | 2015-05-15 | Diagnostic test and treatment/prevention of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016014779A true MX2016014779A (es) | 2017-04-13 |
Family
ID=54480752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016014779A MX2016014779A (es) | 2014-05-16 | 2015-05-15 | Prueba de diagnostico y tratamiento/prevencion de la enfermedad de alzheimer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160206714A1 (es) |
EP (1) | EP3142708A4 (es) |
JP (1) | JP2017521092A (es) |
KR (1) | KR20170040782A (es) |
CN (1) | CN106573075A (es) |
AU (1) | AU2015258996A1 (es) |
BR (1) | BR112016026694A2 (es) |
CA (1) | CA2978409A1 (es) |
IL (1) | IL248935A0 (es) |
MX (1) | MX2016014779A (es) |
SG (1) | SG11201609389QA (es) |
WO (1) | WO2015175898A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101989383B1 (ko) * | 2017-04-04 | 2019-06-14 | 조선대학교산학협력단 | 알츠하이머성 치매의 조기진단을 위한 펩타이드 프로브 |
WO2020045962A1 (ko) * | 2018-08-27 | 2020-03-05 | 광주과학기술원 | 알츠하이머성 치매 진단용 펩타이드 바이오마커 |
CN116705141B (zh) * | 2022-12-15 | 2024-01-09 | 西北大学 | 一种基于cnn-lstm神经网络从核桃酶解产物中筛选阿尔兹海默症预防肽的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100450551C (zh) * | 2002-11-29 | 2009-01-14 | 中国医学科学院基础医学研究所 | 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途 |
WO2008148490A1 (en) * | 2007-06-04 | 2008-12-11 | F. Hoffmann-La Roche Ag | Hsp27 as biomarker for alzheimer's disease |
-
2015
- 2015-05-15 CA CA2978409A patent/CA2978409A1/en not_active Abandoned
- 2015-05-15 CN CN201580036443.9A patent/CN106573075A/zh active Pending
- 2015-05-15 SG SG11201609389QA patent/SG11201609389QA/en unknown
- 2015-05-15 MX MX2016014779A patent/MX2016014779A/es unknown
- 2015-05-15 US US14/911,381 patent/US20160206714A1/en not_active Abandoned
- 2015-05-15 WO PCT/US2015/031011 patent/WO2015175898A1/en active Application Filing
- 2015-05-15 BR BR112016026694A patent/BR112016026694A2/pt not_active Application Discontinuation
- 2015-05-15 EP EP15793658.4A patent/EP3142708A4/en not_active Withdrawn
- 2015-05-15 KR KR1020167035095A patent/KR20170040782A/ko unknown
- 2015-05-15 JP JP2017512868A patent/JP2017521092A/ja active Pending
- 2015-05-15 AU AU2015258996A patent/AU2015258996A1/en not_active Abandoned
-
2016
- 2016-11-13 IL IL248935A patent/IL248935A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2015258996A1 (en) | 2016-12-01 |
IL248935A0 (en) | 2017-01-31 |
KR20170040782A (ko) | 2017-04-13 |
CA2978409A1 (en) | 2015-11-19 |
JP2017521092A (ja) | 2017-08-03 |
CN106573075A (zh) | 2017-04-19 |
SG11201609389QA (en) | 2016-12-29 |
EP3142708A1 (en) | 2017-03-22 |
WO2015175898A1 (en) | 2015-11-19 |
EP3142708A4 (en) | 2018-01-17 |
BR112016026694A2 (pt) | 2017-10-31 |
US20160206714A1 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014367A (es) | Anticuerpos tau humanizados en enfermedad de alzheimer. | |
MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
MX2020001193A (es) | Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. | |
MX2019003473A (es) | Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes. | |
BR112016003868A8 (pt) | Método, aparelho, mídia de armazenamento não transitório, e, programa de computador | |
EP4321866A3 (en) | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
MX2018001697A (es) | Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. | |
MX2018006189A (es) | Lactoferrina para uso en el diagnostico o el pronostico de la enfermedad de alzheimer o en el diagnostico de la enfermedad de parkinson. | |
MX2018014047A (es) | Firmas de genes estromales para el diagnóstico y uso en inmunoterapia. | |
WO2015168602A3 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease | |
MX2016014779A (es) | Prueba de diagnostico y tratamiento/prevencion de la enfermedad de alzheimer. | |
MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
SG11201900972UA (en) | Health-level measuring method, health-level determining apparatus, and hair-health examination system | |
EP3502128A3 (en) | Epitope | |
MX2017006959A (es) | Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable. | |
WO2016133449A9 (en) | Detection and treatment of malignant tumours in the cns | |
MX2016009490A (es) | Ensayo novedoso para detectar periostina humana. | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
BR112019006404A2 (pt) | métodos para diagnóstico e tratamento de câncer de próstata metastático resistente à castração sensível ou resistente a acetato de abiraterona-glicocorticoide | |
BR112019006422A2 (pt) | anticorpo monoclonal contra fzd10 e utilização do mesmo | |
GB201222554D0 (en) | Diagnostic for determining skeletal health |